Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as colorectal cancer.

Abstract: This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF.

Abstract: Devices, systems, and methods for delivery and deployment of an implantable device. The implantable device may be an anchor. The device includes an anchor garage configured to deliver the anchor, therein, to a target site, and an atraumatic shield movable with respect to the anchor garage. A biasing element biases the atraumatic shield into position with respect to the anchor garage. In some embodiments, the distal end of the anchor garage is a sharp tissue-penetrating end, and the atraumatic shield is biased distally over such sharp end. A limit stop may be provided to limit the extent to which the anchor garage extends distally, thereby limiting tissue penetration by the anchor garage and the depth of deployment of the anchor. An indicator may be positioned and/or configured to provide an indication of the relative positions of the anchor garage and the atraumatic shield.

Abstract: Embodiments herein relate to implantable systems for cancer treatment and related methods. In an embodiment, an implantable system for cancer treatment can be included having a therapy output circuit configured to generate an electrical output for one or more electrodes to create one or more electric fields. The implantable system can include control circuitry that causes the therapy output circuit to generate the one or more electric fields at frequencies between 10 kHz and 1 MHz within a bodily tissue. The one or more electric fields can be effective to prevent and./or disrupt cellular mitosis in a cell. The implantable system can further include a therapy zone temperature sensor. The implantable system can be configured to measure the temperature and/or record the temperature data of a patient over time. The temperature data can include tissue temperature and time stamps of the same. Other embodiments are also included herein.

Abstract: Electrical stimulation devices can be used to treat tinnitus. For example, tinnitus can be treated using implantable electrodes and stimulation devices for delivering electrical stimulation to a patient's cochlear region. Cochlear surface electrode(s), endosteal electrode(s), subendosteal electrode(s), intraosseous electrode(s), or short intracochlear electrode(s) (or a combination thereof), connected to existing or modified cochlear implant receiver/stimulator technology, can provide a successful model for long-term treatment of tinnitus in a large number of patients. In some cases, patients can simply turn on the tinnitus implant when experiencing troublesome tinnitus and gain instant relief.

Abstract: This specification discloses systems, methods, devices, and other techniques for determining the location of a seizure-generating region of the brain of a mammal.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: This document provides methods and materials for using low coverage whole genome sequencing techniques to assess genomes. For example, methods and materials for using targeted nucleic acid amplification and/or capture techniques in combination with low coverage whole genome sequencing techniques to obtain high coverage sequencing data for one or more pre-selected regions of a genome are provided.

Abstract: Disclosed herein are systems, devices, and methods for accessing a subdural space. In some embodiments, an apparatus may comprise a shaft configured to be slidably disposed within a lumen of a catheter. The shaft may be configured to be advanced distally from a distal end of the catheter and into a blood vessel of a subject. The shaft may include a perforating tip including an energy element configured to generate radiofrequency energy to form an opening through a wall of the blood vessel and dura of the subject and into an extravascular space of the subject. A curved section may be configured to be radially constrained within the lumen of the catheter and to curve toward the wall of the blood vessel and the dura upon exiting the lumen of the catheter such that the energy element is positioned to form the opening.

Abstract: A trans-illuminating needle guide device for guiding a needle into and illuminating an arteriovenous (AV) fistula in a subject includes: a housing comprising a base, a needle guide insert having a pair of opposing side walls defining a first angled slot, a second angled slot, and a plurality of grooves, a needle guide having a guide channel configured to receive the needle, a first deflectable plate configured to be received by the first angled slot and the plurality of grooves, and a second deflectable plate configured to be received by the second angled slot, a first plurality of light emitting diodes (LEDs) disposed within the housing and configured to emit light of a first wavelength, and a second plurality of LEDs disposed within the housing and configured to emit light of a second wavelength, the second wavelength differing from the first wavelength.

Abstract: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: or a pharmaceutically acceptable salt thereof.

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

Abstract: A gastric bypass device includes an occlusion device that is adapted to be deployed relative to a patient's pyloric sphincter, an anastomosis anchor that is adapted to be deployed relative to an anastomosis between the patient's stomach and their small intestine, and a tether that extends through the patient's small intestine between the occlusion device and the anastomosis anchor. A dynamic leash may be secured relative to the occlusion device and may work in conjunction with the tether to help hold the occlusion device in place. The gastric bypass device may be deployed using a variety of methods including a push-pull wire method, a rail method, a garage method, a two-piece method and a comprehensive method.

Abstract: A gastric bypass device includes an occlusion device that is adapted to be deployed relative to a patient's pyloric sphincter and a liner that extends distally from the occlusion device. A tether extends from the occlusion device. A dynamic leash may be secured relative to the occlusion device and may work in conjunction with the tether to help hold the occlusion device in place.

Abstract: This specification discloses a brain electrode device. The brain electrode device includes a set of contact points and a set of sub-circuits. The sub-circuits include sensor ports configured to connect to the contact to the respective ones of the contact points. The device can further include an intelligent multiplexer that aggregates signals from the set of sub-circuits and generates an aggregate signal. The aggregate signal is transmitted to a signal acquisition device.

Abstract: Complexes containing a labeled polypeptide and an antibody, and the use of such complexes as research, diagnostic, and clinical tools, are described herein.

Abstract: This document describes methods and devices for treating ventricular fibrillation. For example, this document describes methods of performing electroporation of a ventricle and electroporation catheters. The methods can include inserting a distal end portion of a catheter into a ventricle of a heart of a patient, inflating a balloon coupled to the distal end portion of the catheter, occluding a valve of the heart associated with the ventricle with the balloon, injecting a fluid into the ventricle via an aperture defined by the distal end portion of the catheter, and generating an electrical current via an electrode on the distal end portion of the catheter.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: This document provides methods and materials related to selected engineered analogs of atrial natriuretic peptides. For example, this document provides compositions that contain one or more selected engineered analogs of atrial natriuretic peptides provided herein and that have the ability to treat, prevent, or alleviate the symptoms of cardiovascular, cardiorenal, and metabolic disease.

Abstract: The present invention relates to methods and compositions for determination of and uses of specific methylation patterns indicative of adenoma and carcinoma. In particular, the invention relates to analysis of defined CpG loci that are coordinately methylated in DNAs from cancer and adenoma samples, methods for identifying coordinately methylated loci, and methods of using analysis of coordinately methylated loci in one or more marker regions in the design of assays for adenoma and cancer.